2020 Ophthalmic Telemedicine and the CMS 1135 Waiver

Changes aim to ease diagnosis and management of retinal disease.

By RIVA LEE ASBELL

Targeting RNA for Retinal Disease

RNA-based gene therapy is primed for a resurgence in retina.

By Michael Gemayel, MD, Thomas A. Ciulla, MD, MBA

Management of and Controversies in Autoimmune Retinopathy

Controversy lingers around diagnosis.

By DAVID R.P. ALMEIDA, MD, MBA, PHD, Eric K. Chin, MD, and

Covering Call for Pediatric Retina Patients

Establishing a pediatric retina call service.

By Cagri G. Besirli, MD, PhD, Vaidehi S. Dedania, MD

New Updates on Gene-Derived Anti-VEGF

Adverum and Regenxbio continue to report positive early results.

By Jerry Helzner, contributing editor

SUBSPECIALTY NEWS: Coronavirus impact on industry, clinical trials, and retina practice.

By Jerry Helzner, contributing editor

Disorganization of the Retinal Inner Layers as a Prognostic Biomarker

This OCT biomarker has potential importance across multiple retinal pathologies.

By Archana Nair, MD, Yasha Modi, MD

Pharmacotherapy as an Adjunct to Vitrectomy for Retinal Disease

Pharmacotherapy remains a critical component in the management of complex retinal disease.

By Veronica Kon Graversen, MD, Aaron Gold, OD, Timothy G. Murray, MD, MBA, FACS

UPFRONT: A New World of Communication and Education in Retina

By Peter K. Kaiser, MD

FUTURE FILE: Highlighting innovative early-stage and preclinical concepts in retina

By Jerry Helzner, contributing editor

NEW PRODUCT APPLICATIONS: Registry Offers Resources to Inherited Retinal Disease Patients

Offerings include genetic testing and counseling, notifications of clinical studies, and more

By Karen Appold, contributing writer

CLINICAL TRIAL UPDATE

Industry Opportunities for Retina Specialists

Personal perspectives on transitioning to careers in the corporate world.

By Susan L. Worley, contributing writer